B019

B019 is a bicistronic chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target CD19 and CD22 antigens on B-cell malignancies. Developed to overcome antigen escape—a common mechanism of resistance to single-target CAR-T therapies—B019 utilizes a single viral vector to express two distinct CAR constructs. In a large clinical trial of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), B019 demonstrated a high complete remission rate (99.1%) and durable responses, including in patients with extramedullary disease. The therapy is associated with manageable cytokine release syndrome (CRS) and neurotoxicity.

Other names

bicistronic CD19/CD22 CAR T-cellCD19/CD22 bicistronic CAR-T